CANF
Price
$1.04
Change
+$0.01 (+0.97%)
Updated
Jun 27 closing price
Capitalization
13.67M
RNA
Price
$29.03
Change
-$0.80 (-2.68%)
Updated
Jun 27 closing price
Capitalization
3.5B
43 days until earnings call
Interact to see
Advertisement

CANF vs RNA

Header iconCANF vs RNA Comparison
Open Charts CANF vs RNABanner chart's image
Can-Fite BioPharma
Price$1.04
Change+$0.01 (+0.97%)
Volume$107.37K
Capitalization13.67M
Avidity Biosciences
Price$29.03
Change-$0.80 (-2.68%)
Volume$1.31M
Capitalization3.5B
CANF vs RNA Comparison Chart in %
Loading...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CANF vs. RNA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Buy and RNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CANF: $1.04 vs. RNA: $29.03)
Brand notoriety: CANF and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 93% vs. RNA: 97%
Market capitalization -- CANF: $13.67M vs. RNA: $3.5B
CANF [@Biotechnology] is valued at $13.67M. RNA’s [@Biotechnology] market capitalization is $3.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, CANF is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 2 TA indicator(s) are bullish while RNA’s TA Score has 2 bullish TA indicator(s).

  • CANF’s TA Score: 2 bullish, 4 bearish.
  • RNA’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CANF is a better buy in the short-term than RNA.

Price Growth

CANF (@Biotechnology) experienced а -1.42% price change this week, while RNA (@Biotechnology) price change was -0.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

RNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($3.5B) has a higher market cap than CANF($13.7M). RNA YTD gains are higher at: -0.172 vs. CANF (-36.000). RNA has more cash in the bank: 1.38B vs. CANF (995K). CANF has less debt than RNA: CANF (40K) vs RNA (5.97M).
CANFRNACANF / RNA
Capitalization13.7M3.5B0%
EBITDAN/A-430.35M-
Gain YTD-36.000-0.17220,938%
P/E RatioN/AN/A-
RevenueN/A8.93M-
Total Cash995K1.38B0%
Total Debt40K5.97M1%
FUNDAMENTALS RATINGS
CANF: Fundamental Ratings
CANF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CANFRNA
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 18 days ago
85%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JHTGX19.630.08
+0.41%
JPMorgan Hedged Equity 3 R5
TSVAX16.440.05
+0.31%
PGIM Quant Solutions Small-Cap Val A
CDDRX35.350.09
+0.26%
Columbia Dividend Income Inst2
MSSCX8.600.01
+0.12%
AMG Frontier Small Cap Growth I
VSVIX29.12-0.02
-0.07%
Victory Integrity Small-Cap Value Y

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with LGVN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then LGVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
+0.97%
LGVN - CANF
38%
Loosely correlated
+1.54%
OABI - CANF
35%
Loosely correlated
+0.59%
GBIO - CANF
29%
Poorly correlated
-15.40%
RNA - CANF
27%
Poorly correlated
-2.68%
IPSC - CANF
26%
Poorly correlated
-5.74%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with ACLX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
-2.68%
ACLX - RNA
57%
Loosely correlated
+0.90%
DYN - RNA
56%
Loosely correlated
-4.78%
NRIX - RNA
55%
Loosely correlated
+0.17%
OCUL - RNA
51%
Loosely correlated
-2.54%
STOK - RNA
50%
Loosely correlated
-1.77%
More